Home MarketWockhardt Ltd.

Wockhardt Ltd. Stock Info: As on 2017-11-24 15:59:57

Nse

709.65

-7.45(-1.04%)
Change%
52 Week Range
530.65
22.00
788.65
7.00
Open717.00
Day's Range645.39 - 788.81
Value Traded (in ₹ Cr.) 43.09

Bse

710.50

-5.50(-0.77%)
Change %
52 Week Range
531.50
22.00
788.40
7.00
Open717.00
Day's Range644.40 - 787.60
Value Traded (in ₹ Cr.) 8.92

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 81,985,382.00 74.15%
Mutual Funds/UTI 2,744,370.00 2.48%
FII 4,132,544.00 3.74%
Employee 0.00 0.00%
Public 15,775,772.00 14.27%
Government 0.00 0.00%
Others 4,219,564.00 3.82%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.83
Basic EPS (Rs.) 2.97
Cash EPS 12.18
BVPerShare Excl 98.68
Operating Revenue 201.33
PBDITPerShare 16.73
Dividend 0.00
NPPerShare 2.97
Current Ratio 1.52
Quick Ratio 1.10
PriceToBV 9.86
Earnings 0.00
PBDIT Margin 8.31
PBT Margin 0.14
NP Margin 1.47
Return On Assets 0.70
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,281.05
Total Expenses 2,277.84
EBITDA 184.91
PBT 3.21
PAT 32.79
Net Income 32.79
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,177.86
Total Expenses 1,063.80
EBITDA 62.33
PBT 62.12
PAT 96.85
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

535.05 535.15 -0.02
525.05537

Abbott India Ltd.

4977.5 4858.7 2.45
4810.055049

Ajanta Pharma Ltd.

1329.2 1327.15 0.15
12301362.3

Albert David Ltd.

361.2 323.55 11.64
285.5328

Alembic Ltd.

39.35 39.25 0.25
3940.45

Alembic Pharmaceuticals Ltd.

515.5 514.3 0.23
507.4525.45

Alkem Laboratories Ltd.

1987.9 1974.45 0.68
19442013.85
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

56.5 53.35 5.9
44.0558.4

Aarti Drugs Ltd.

532.1 532 0.02
513.4537

Aayush Food & Herbs Ltd.

47.7 47.9 -0.42
40.152.7

Abbott India Ltd.

4968.65 4861.15 2.21
48505085

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities -363.18
Cash from investing activities -1,015.33
Cash from financing activities 763.89
Net change in cash -614.39

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Aditya Birla Sun Life Enhanced Arbitrage Fund 0.34%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.09%
Kotak Equity Arbitrage Fund - Regular Plan 0.11%
HDFC Capital Builder Fund - Regular Plan 0.66%
Reliance Arbitrage Advantage Fund 0.12%
UTI Spread Fund 0.49%

Cadila bags approval for Minocycline Hydrochloride tablets

Cadila Healthcare Ltd has said that its arm Zydus Pharmaceuticals (USA) Inc. has received the final approval from the USFDA to market Minocycline Hydrochloride Extended - Release Tablets in strengths of 45 mg, 80 mg, 90 mg and 105 mg and 135 mg. Zydus also received the tentative approval for Minocycline Hydrochloride Extended - Release Tablets, 55 mg, 65 mg and 115 mg. “Minocycline Hydrochloride Extended - Release Tablets are a tetracycline-class drug, indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad,” the company said in a filing to the Bombay Stock Exchange. The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, shares of the company were trading at Rs 446.35 apiece, up 0.64 per cent from the previous close at 11:05 hrs on BSE.

24-11-2017 11:01

Revathi Equipment Ltd posts Q2 net profit of Rs 0.27 cr

The company reported standalone net profit during the quarter stood at Rs 0.27 crore compared to net loss of Rs 1.00 crore in the previous year quarter. Net revenue of the company declined by 0.46 per cent at Rs 10.81 crore in July-September quarter of this fiscal as against Rs 10.86 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 8.47 per cent to Rs 9.72 crore from Rs 10.62 crore in year ago period. Other Income dipped by 4.76 per cent at Rs 0.40 crore versus (Sep'16 Rs 0.42 crore). Operating Profit surged by 354.17 per cent to Rs 1.09 crore as against Rs 0.24 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 348.89 per cent in September quarter. Interest declined by 58.05 per cent y-o-y to Rs 0.73 crore, while Taxation increased by 257.14 per cent at Rs 0.33 crore (Sep'16 Rs -0.21 crore).

24-11-2017 10:27

Salasar Techno Q2 net profit jumps 41.61% at Rs 4.05 cr

The company reported standalone net profit of Rs 4.05 crore for the quarter ended September 30, 2017 as compared to Rs 2.86 crore in the same period last year, registering a year-on-year growth of 41.61 per cent. Net revenue of the company rose substantially by 31.30 per cent at Rs 95.22 crore in July-September quarter of this fiscal as against Rs 72.52 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 32.08 per cent to Rs 89.42 crore from Rs 67.70 crore in year ago period. Other Income grew by 20.00 per cent at Rs 0.06 crore versus (Sep'16 Rs 0.05 crore). Operating Profit surged by 20.12 per cent to Rs 5.79 crore as against Rs 4.82 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 8.28 per cent in September quarter. Interest grew by 16.13 per cent y-o-y to Rs 0.36 crore, while Taxation decreased by 29.17 per cent at Rs 1.53 crore (Sep'16 Rs 2.16 crore).

24-11-2017 10:27

Sunil Healthcare Q2 net profit down 53.80% at Rs 0.79 cr

The company reported standalone net profit of Rs 0.79 crore for the quarter ended September 30, 2017 as compared to Rs 1.71 crore in the same period last year, registering a year-on-year decline of 53.80 per cent. Net revenue of the company declined by 5.58 per cent at Rs 22.85 crore in July-September quarter of this fiscal as against Rs 24.20 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 1.65 per cent to Rs 19.70 crore from Rs 20.03 crore in year ago period. Other Income grew by 11.76 per cent at Rs 0.19 crore versus (Sep'16 Rs 0.17 crore). Operating Profit slipped by 27.08 per cent to Rs 3.15 crore as against Rs 4.32 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 22.86 per cent in September quarter. Interest grew by 0.99 per cent y-o-y to Rs 1.02 crore, while Taxation decreased by 49.28 per cent at Rs 0.35 crore (Sep'16 Rs 0.69 crore).

24-11-2017 10:27

RIL’s arm closes sale of assets to BKV Chelsea

Reliance Industries Limited has said that its arm Reliance Marcellus II, LLC a subsidiary of Reliance Holding USA, Inc. has closed recently announced sale of its interest in certain upstream assets; which were operated by Carrizo Oil & Gas, Inc to BKV Chelsea LLC, an affiliate of Kalnin Ventures. In a transaction announced on October 06, 2017, Reliance agreed to sell its entire working interest in these upstream assets to BKV Chelsea for purchase consideration of USD 126 million with an effective date of April 01, 2017. Additionally, under the definitive documents, a contingent amount of up to USD 11.25 million may be paid to Reliance between years 2018 to 2020 based on certain gas price thresholds being achieved. The transaction closed on November 21, 2017 and Reliance received the purchase consideration subject to usual and customary purchase price adjustments. Meanwhile, shares of the company were trading at Rs 954.95 apiece, up 1.04 per cent from the previous close at 10:05 hrs on BSE.

24-11-2017 10:00

Wockhardt Q2 net profit down 82.68% at Rs 25.32 cr

The company reported standalone net profit of Rs 25.32 crore for the quarter ended September 30, 2017 as compared to Rs 146.16 crore in the same period last year, registering a year-on-yeardeclineof 82.68 per cent. Net revenue of the company declined marginally by 1.56 per cent at Rs 588.93 crore in July-September quarter of this fiscal as against Rs 598.28 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 6.99 per cent to Rs 535.74 crore from Rs 576.00 crore in year ago period. Other Income dipped by 93.51 per cent at Rs 12.23 crore versus (Sep'16 Rs 188.57 crore). Operating Profit surged by 138.73 per cent to Rs 53.19 crore as against Rs 22.28 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 142.74 per cent in September quarter. Interest grew by 2.81 per cent y-o-y to Rs 43.50 crore, while Taxation increased by 545.90 per cent at Rs -29.13 crore (Sep'16 Rs -4.51 crore).

31-Oct-2017 05:10 PM

Wockhardt Ltd. - Press Release / Media Release

We wish to enclose herewith:

a) Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended
30th September, 2017, as approved by the Board of Directors at its meeting held today;

b) Limited Review Report issued by Haribhakti & Co. LLP., Statutory Auditors of the Company for the quarter ended 30th September, 2017;

c) Copy of Press Release proposed to be issued in respect of the said Financial Results; and

d) Extract of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2017 being published in the Newspapers

Further, in terms of Regulation 30 of the Listing Regulations, we would like to inform that Board of Directors in its meeting held today have inducted Ms. Zahabiya Khorakiwala (DIN: 00102689) as Additional Director (Non-Executive) w.e.f. 30th October, 2017.

30-Oct-2017 01:32 PM

Wockhardt Ltd. - Financial Results For Quarter And Half Year Ended 30Th September, 2017

We wish to enclose herewith:

a)Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended
30th September, 2017, as approved by the Board of Directors at its meeting held today;

b)Limited Review Report issued by Haribhakti & Co. LLP., Statutory Auditors of the Company for the quarter ended 30th September, 2017;
c)Copy of Press Release proposed to be issued in respect of the said Financial Results; and

d)Extract of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2017 being published in the Newspapers

Further, in terms of Regulation 30 of the Listing Regulations, we would like to inform that Board of Directors in its meeting held today have inducted Ms. Zahabiya Khorakiwala (DIN: 00102689) as Additional Director (Non-Executive) w.e.f. 30th October, 2017

30-Oct-2017 01:30 PM

Wockhardt Ltd. - Press Release

Wockhardt Limited has informed the Exchange regarding a press release dated October 30, 2017, titled Press Release- Financial Results.

30-Oct-2017 01:26 PM

Wockhardt Ltd. - Financial Result Updates

Wockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

30-Oct-2017 01:26 PM

Wockhardt Ltd. - Press Release / Media Release

We wish to enclose herewith:

a) Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended
30th September, 2017, as approved by the Board of Directors at its meeting held today;

b) Limited Review Report issued by Haribhakti & Co. LLP., Statutory Auditors of the Company for the quarter ended 30th September, 2017;

c) Copy of Press Release proposed to be issued in respect of the said Financial Results; and

d) Extract of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2017 being published in the Newspapers

Further, in terms of Regulation 30 of the Listing Regulations, we would like to inform that Board of Directors in its meeting held today have inducted Ms. Zahabiya Khorakiwala (DIN: 00102689) as Additional Director (Non-Executive) w.e.f. 30th October, 2017.

30-Oct-2017 01:32 PM

Wockhardt Ltd. - Financial Results For Quarter And Half Year Ended 30Th September, 2017

We wish to enclose herewith:

a)Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended
30th September, 2017, as approved by the Board of Directors at its meeting held today;

b)Limited Review Report issued by Haribhakti & Co. LLP., Statutory Auditors of the Company for the quarter ended 30th September, 2017;
c)Copy of Press Release proposed to be issued in respect of the said Financial Results; and

d)Extract of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2017 being published in the Newspapers

Further, in terms of Regulation 30 of the Listing Regulations, we would like to inform that Board of Directors in its meeting held today have inducted Ms. Zahabiya Khorakiwala (DIN: 00102689) as Additional Director (Non-Executive) w.e.f. 30th October, 2017

30-Oct-2017 01:30 PM

Wockhardt Ltd. - Appointment of Director

In terms of Regulation 30 of the Listing Regulations, we would like to inform that Board of Directors in its meeting held today (i.e. 30th October, 2017) have inducted Ms. Zahabiya Khorakiwala (DIN: 00102689) as Additional Director (Non-Executive) w.e.f. 30th October, 2017. Brief profile of Ms. Zahabiya Khorakiwala is as under:-

'Ms. Zahabiya Khorakiwala, Master's in Business Administration from the Indian School of Business has an experience of more than a decade in the area of strategy and leadership. Presently, Ms. Zahabiya is heading Wockhardt Hospitals as the Managing Director and is responsible to strategic decisions, identifying new business opportunities, creating viable and sustainable business models to drive growth of overall operations of the hospital chain.

Ms. Zahabiya is also a Director on the Board of RPG Life Sciences Limited and other corporates.'

30-Oct-2017 01:25 PM

Corporate Details

About Management

YEAR EVENTS 2000 - Wockhardt has launched cardiac drug enalapril maleate in the US through its marketing joint venture with Sidmak Laboratories. - Pharmaceutical major Wockhardt Ltd has set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. 2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of Wockhardt Ltd, will set up two cardiac hospitals in Mumbai and Bangalore. - The Company has terminated its three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic pharma companies in the US. - Pharma major Wockhardt Ltd. has entered into a strategic alliance with a Japanese firm Eisai Company Ltd. to manufacture and market a neurology drug -- Methycobal. - Wockhardt Hospitals Ltd, the wholly owned subsidiary of pharmaceutical major Wockhardt Ltd, has tied up with four international health insurance companies to offer medical cover to non-resident Indians. - AGM JUNE 8 2001 Wockhardt has launched an innovative and attractive employee stock option scheme, ESOP. - Wockhardt Ltd has introduced an employee stock option (ESOP) scheme for over 175 employees in the senior and middle management levels with about 2,00,000 shares being allotted. 2002 -The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra will spearhead the company's domestic operations which account for 70 per cent of its turnover. - Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director on its Corporate Board. Mr. Kumar will spearhead Wockhardt's International Business covering bulk drug operations and formulations export, as well as ANDA research and Intellectual Property Rights. 2003 -Wockhardt restructured its field organization to upgrade its competitiveness and productivity. -Mumbai based wockhardt will hit the domestic market with the first indigenously developed insulin soon, in a move to induce turmoil in the market. -Wockhardt has launched new four speciality hospitals at its Mulund complex in Mumbai. -Maharashtra Government decided to terminate its Joint Venture agreement with Wockhardt for setting up a super speciality hospital. -Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd, along with its subsidiaries. -Wockhardt is strengthening its marketing strategies and distribution system to unveil human insulin in Indian market. -Wockhardt Launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. -Wockhardt Ltd has received USFDA approval for marketing bethanecol Chloride tablets in the US. -Wockhardt baged USFDA approval for Bethanechol -Baged US approval to sell bethanechol chloride tablets -Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on the board of the company as Executive Director, has resigned from the directorship with immediate effect. 2004 -Wockhardt Ltd has filed an Investigational New Drug (IND) application for its new drug for respiratory infections, WCK-1152 - Wockhardt Ltd has acquired German pharmaceutical company esparma GmbH for a consideration of $11 million (around Rs 49 crore). -Centre for Drug Evaluation & Research, an arm of the US Food & Drug Administration (US FDA), has approved the sterile injectable facility as well as facilities for sterile bulk drugs (active pharmaceutical ingredient) and formulations spread over three locations in India -Wockhardt gets USFDA nod for 6 manufacturing units 2005 -Launches of India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients on February 14, 2005 -Wockhardt forges alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad -Wockhardt unveils father`s heart network -Wockhardt receives US FDA approval for marketing cefuroxime axetil in the US market -Wockhardt unveils new generation hepatitis A vaccine -Wockhardt rolls out new Hepatitis A vaccine 2006 -Wockhardt's Waluj plant approved by US FDA 2007 -Wockhardt signs in-licensing pact with Crawford Healthcare of UK. -Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance & Information for a period of five years effective from February 22, 2007, subject to the approval of shareholders. -Wockhardt Ltd has announced US FDA approval for marketing Ketorolac anti-inflammatory injection in the US market, its third US FDA approval in the last ten days. - Wockhardt Ltd on May 03, 2007 has announced the acquisition of Negma Laboratories, the fourth largest independent, integrated pharmaceutical group in France with sales of $ 150 million. The Company has acquired Negma Laboratories in an all-cash deal worth $ 265 million. The transaction is valued at 1.8 times the sales and 9.7 times the EBITDA. 2008 Wockhardt Ltd has unveiled Cetirizine tablets in the US, after having got the regulatory clearance to market different strengths of anti-allergy medicine Cetirizine Hydrochloride. Cetirizine is the generic version of Pfizer's Zyrtec brand and the total market for Cetirizine tablets in the US is $1.4 billion. - Wockhardt Ltd has forayed into a 10- year in-licensing pact with the UK's Sinclair Pharma plc to market dermatology and dental products in India. 2009 -A biotechnology breakthrough in Diabetes Wockhardt launches new insulin (Glaritus) in India. -Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes. -Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala. -Wockhardt launches anti-hypertensive drug Nicardipine injections in USA. -Wockhardt wins Government of India Patent Award. -Wockhardt appoints BDO Haribhakti as auditor. -Wockhardt announces Entacapone patent settlement with Orion Corporation. 2010 -Wockhardt receives US FDA approval for antibacterial Levofloxacin -Wockhardt launches Prostate drug Flomax in the United States on Day-1. -Wockhardt receives US FDA approval for the generic version of Toprol XLr, a cardiac drug. 2011 -Wockhardt launches generic version of Protonixr tablets in the US. -Wockhardt receives US FDA approval for generic version of Effexor XRr capsules. -Wockhardt launches three new products in three weeks, in the United States. -Wockhardt receives tentative US FDA approval for generic version of Patanolr ophthalmic solution. 2012 -Wockhardt launches generic version of anti--ulcer drug Prevacidr. -Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XLr. -Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodonr. -Wockhardt receives US FDA approval for generic version of Parkinson's drug Comtanr. 2013 -Wockhardt receives the 'Best Enterprise' award from the Europe. -Wockhardt launches generic version of anti-convulsant drug Lamictal XR. 2014 -Wockhardt's drug discovery gets a boost with fast track approval by USFDA. 2015 -Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt 2015 -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -Wockhardt receives ANDA approval for pain medication Oxycodone liquid -Wockhardt gains over 2% after MHRA completes plant inspection -Wockhardt gets QIDP status for new antibiotic from US FDA.

Registered Office

PO Barotiwala,

01795-664444,,,      01795-664312,

Registrar Details

Link Intime India Pvt. Ltd.